Effects of Apolipoprotein E Isoforms in Diabetic Nephropathy of Chinese Type 2 Diabetic Patients

被引:12
|
作者
Jiang, YongWei [1 ]
Ma, Liang [2 ,3 ]
Han, ChengWu [1 ]
Liu, Qian [1 ]
Cong, Xiao [1 ]
Xu, YaPing [4 ]
Zhao, TingTing [3 ]
Li, Ping [2 ,3 ]
Cao, YongTong [1 ]
机构
[1] China Japan Friendship Hosp, Clin Lab, Beijing, Peoples R China
[2] Peking Union Med Coll, Grad Sch, Beijing, Peoples R China
[3] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing Key Lab Immune Mediated Inflammatory Dis, Beijing, Peoples R China
[4] China Japan Friendship Hosp, Inst Clin Med Sci, Dept Pathophysiol, Beijing, Peoples R China
关键词
E GENE POLYMORPHISM; RENAL-DISEASE; APOE POLYMORPHISM; KIDNEY-DISEASE; ASSOCIATION; PROGRESSION; MELLITUS; SUSCEPTIBILITY; POPULATION; METABOLISM;
D O I
10.1155/2017/3560920
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic nephropathy (DN) is one of the major chronic complications of diabetes. Genetic polymorphism of Apolipoprotein E (ApoE) has been proposed to participating in DN. The purpose of the study was to evaluate the relationship between ApoE genetic polymorphism and the presence of DN in Chinese type 2 diabetic patients. We studied 845 diabetic patients who were divided into DN group (n = 429) and control group (n = 416). ApoE genotype was determined by ApoE genotyping chip and the plasmatic biochemical characterization was performed on all subjects. There were differences (P < 0.001) in HbA1c, creatinine, and urinary albumin between the two groups. The ApoE epsilon 2 allelic frequency was 7.69% in DN group versus 3.49% in control group (OR = 2.22, 95% CI = 1.41-3.47, and P < 0.05), as expected, ApoE E2/E2 and E2/E3 genotype frequency were higher in DN group (13.75% versus 6.49%, P < 0.05). The ApoE epsilon 4 allelic frequency was 7.93% in DN group versus 11.54% in control group (OR = 0.70, 95% CI = 0.50-0.97, and P < 0.05), and DN group presented a lower frequency of ApoE E3/E4 and E4/E4 genotype frequency (14.91% versus 19.96% P < 0.05). These results suggest ApoE epsilon 2 allele may be a risk factor; however ApoE epsilon 4 allele may play a protective role of DN in Chinese type 2 diabetic patients.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients
    Temesgen Fiseha
    Biomarker Research, 3 (1)
  • [32] Analysis of epistasis for diabetic nephropathy among type 2 diabetic patients
    Hsieh, Chang-Hsun
    Liang, Kung-Hao
    Hung, Yi-Jen
    Huang, Li-Chin
    Pei, Dee
    Liao, Ya-Tang
    Kuo, Shi-Wen
    Bey, Monica Shian-Jy
    Chen, Jui-Lin
    Chen, Ellson Y.
    HUMAN MOLECULAR GENETICS, 2006, 15 (18) : 2701 - 2708
  • [33] Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients
    Fiseha, Temesgen
    BIOMARKER RESEARCH, 2015, 3
  • [34] Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients
    Canani, LH
    Gerchman, F
    Gross, JL
    DIABETES, 1999, 48 (04) : 909 - 913
  • [35] Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM
    Kimura, H
    Suzuki, Y
    Gejyo, F
    Karasawa, R
    Miyazaki, R
    Suzuki, S
    Arakawa, M
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) : 666 - 673
  • [37] Study on Chinese medicine syndromes in type 2 diabetic nephropathy with or without diabetic retinopathy
    成海梅
    ChinaMedicalAbstracts(InternalMedicine), 2021, 38 (04) : 196 - 197
  • [38] The relationship of the apolipoprotein E gene polymorphism in Turkish Type 2 Diabetic Patients with and without diabetic foot ulcers
    Mehmet, Erdogan
    Zuhal, Eroglu
    Mustafa, Kulaksizoglu
    Soner, Solmaz
    Asli, Tetik
    Sevki, Cetinkalp
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2016, 10 (01) : S30 - S33
  • [39] Apolipoprotein genes in diabetic nephropathy
    Chowdhury, TA
    Kumar, S
    Gough, SCL
    Barnett, AH
    Bain, SC
    DIABETOLOGIA, 1996, 39 : 1142 - 1142
  • [40] Diabetic nephropathy: Renal structural studies in type 1 and type 2 diabetic patients
    Dalla Vestra, M
    Fioretto, P
    METABOLIC SYNDROME: DIABETES, OBESITY, HYPERLIPIDEMIA AND HYPERTENSION, 2003, 1253 : 163 - 169